CN112245584B - Use of polyphosphate inositol phosphatase 1 as target molecule - Google Patents
Use of polyphosphate inositol phosphatase 1 as target molecule Download PDFInfo
- Publication number
- CN112245584B CN112245584B CN202011123674.2A CN202011123674A CN112245584B CN 112245584 B CN112245584 B CN 112245584B CN 202011123674 A CN202011123674 A CN 202011123674A CN 112245584 B CN112245584 B CN 112245584B
- Authority
- CN
- China
- Prior art keywords
- minpp1
- hbv
- gene
- hepatocellular carcinoma
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000006029 inositol monophosphatase Human genes 0.000 title description 4
- 108700003805 myo-inositol-1 (or 4)-monophosphatase Proteins 0.000 title description 4
- 229920000388 Polyphosphate Polymers 0.000 title description 3
- 239000001205 polyphosphate Substances 0.000 title description 3
- 235000011176 polyphosphates Nutrition 0.000 title description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 83
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 58
- 101000573447 Homo sapiens Multiple inositol polyphosphate phosphatase 1 Proteins 0.000 claims abstract description 51
- 102100026284 Multiple inositol polyphosphate phosphatase 1 Human genes 0.000 claims abstract description 50
- 101150114789 MINPP1 gene Proteins 0.000 claims abstract description 44
- 230000012010 growth Effects 0.000 claims abstract description 15
- 230000009545 invasion Effects 0.000 claims abstract description 10
- 230000003213 activating effect Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 230000014509 gene expression Effects 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000002018 overexpression Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 19
- 208000014018 liver neoplasm Diseases 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 8
- 241000700721 Hepatitis B virus Species 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 86
- 210000001519 tissue Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000004110 gluconeogenesis Effects 0.000 description 7
- 230000034659 glycolysis Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000006748 scratching Methods 0.000 description 5
- 230000002393 scratching effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000037353 metabolic pathway Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003208 gene overexpression Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- OXSYGCRLQCGSAQ-UHFFFAOYSA-N CC1CCC2N(C1)CC3C4(O)CC5C(CCC6C(O)C(O)CCC56C)C4(O)CC(O)C3(O)C2(C)O Chemical compound CC1CCC2N(C1)CC3C4(O)CC5C(CCC6C(O)C(O)CCC56C)C4(O)CC(O)C3(O)C2(C)O OXSYGCRLQCGSAQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- -1 small molecule compound Chemical class 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100040385 5-hydroxytryptamine receptor 4 Human genes 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 102100021961 Bis(5'-adenosyl)-triphosphatase ENPP4 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 102100032263 DNA-directed RNA polymerase I subunit RPA49 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100026541 F-actin-capping protein subunit alpha-3 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100030456 Follistatin-related protein 4 Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000964065 Homo sapiens 5-hydroxytryptamine receptor 4 Proteins 0.000 description 1
- 101000897056 Homo sapiens Bis(5'-adenosyl)-triphosphatase ENPP4 Proteins 0.000 description 1
- 101001088155 Homo sapiens DNA-directed RNA polymerase I subunit RPA49 Proteins 0.000 description 1
- 101000983575 Homo sapiens F-actin-capping protein subunit alpha-3 Proteins 0.000 description 1
- 101001062597 Homo sapiens Follistatin-related protein 4 Proteins 0.000 description 1
- 101000945191 Homo sapiens Kelch-like protein 34 Proteins 0.000 description 1
- 101001130171 Homo sapiens L-lactate dehydrogenase C chain Proteins 0.000 description 1
- 101001055386 Homo sapiens Melanophilin Proteins 0.000 description 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 1
- 101001072903 Homo sapiens Phosphoglucomutase-2 Proteins 0.000 description 1
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
- 101000650697 Homo sapiens Roundabout homolog 2 Proteins 0.000 description 1
- 101000651939 Homo sapiens SKI/DACH domain-containing protein 1 Proteins 0.000 description 1
- 101000785978 Homo sapiens Sphingomyelin phosphodiesterase Proteins 0.000 description 1
- 101000688561 Homo sapiens Sphingosine-1-phosphate lyase 1 Proteins 0.000 description 1
- 101000788535 Homo sapiens TBC1 domain family member 31 Proteins 0.000 description 1
- 101000658588 Homo sapiens TP53-target gene 3 protein Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100033581 Kelch-like protein 34 Human genes 0.000 description 1
- 102100034845 KiSS-1 receptor Human genes 0.000 description 1
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 description 1
- 102100031357 L-lactate dehydrogenase C chain Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102100026158 Melanophilin Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 1
- 102100036629 Phosphoglucomutase-2 Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100027739 Roundabout homolog 2 Human genes 0.000 description 1
- 102100027349 SKI/DACH domain-containing protein 1 Human genes 0.000 description 1
- 102100026263 Sphingomyelin phosphodiesterase Human genes 0.000 description 1
- 102100024239 Sphingosine-1-phosphate lyase 1 Human genes 0.000 description 1
- 102100025223 TBC1 domain family member 31 Human genes 0.000 description 1
- 102100034899 TP53-target gene 3 protein Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an application of MINPP1 as a target molecule in preparing a medicine for resisting HBV-related hepatocellular carcinoma, which inhibits the growth and invasion of HBV-related hepatoma cells by over-expressing or activating MINPP1 gene. The invention proves that the MINPP1 gene can be used as an important target spot for effectively inhibiting the proliferation of HBV-related liver cancer cells.
Description
Technical Field
The invention relates to application of a Polyphosphate Inositol Phosphatase 1(Multiple Inositol Phosphatase 1, MINPP1) gene as a target point for resisting hepatocellular carcinoma related to hepatitis B virus.
Background
The primary liver cancer is caused by canceration of related liver cells in vivo, has the characteristics of high malignancy, easy relapse and metastasis, poorer prognosis and the like, and seriously harms the health of human beings. According to statistics, about 84.1 ten thousand new liver cancer cases and 78.1 ten thousand death cases are found in 2018 worldwide. China is a country with high incidence of liver cancer, and about 46 ten thousand new cases occur every year. According to the pathological tissue type, the primary liver cancer can be divided into hepatocellular carcinoma, intrahepatic cholangiocellular carcinoma and mixed cell carcinoma. Among them, Hepatocellular carcinoma (HCC) is a malignant tumor occurring in liver epithelial cells, and is one of the most common pathological types in primary liver cancer.
The risk factors causing the occurrence and development of liver cancer include viral infection, drinking, obesity, eating moldy food, etc. Among them, Hepatitis and cirrhosis caused by chronic infection of virus and the cases that finally develop into hepatocellular carcinoma account for the main proportion of liver cancer patients in our country, while the problem of hepatocellular carcinoma associated with Hepatitis B Virus (HBV) is particularly serious. According to the existing research, many cell signaling pathways are abnormally regulated in the HBV infection process, and the normal functions of liver cells are influenced, such as a p53 signaling pathway, a MAPK signaling pathway, a PI3K/Akt signaling pathway, a TLR-4/MyD88/NF-kB signaling pathway and the like. However, the pathogenic mechanism of HBV-related hepatocellular carcinoma is not completely disclosed, and the therapeutic approaches include surgical resection, radiotherapy and chemotherapy, and small molecule compound drug therapy. Therefore, there is still a need to find more potential targets to provide new approaches for the treatment of HBV-associated hepatocellular carcinoma.
Inositol Polyphosphate Phosphatase 1 (MINPP 1) is a protein mainly localized in endoplasmic reticulum lumen of cells, and has the main function of hydrolyzing various Inositol phosphates and participating in regulation of biological processes such as vesicle trafficking, cell differentiation and the like. Other functions of MINPP1 have also been reported in recent years: sabine et al in vitro experiments demonstrated that MINPP1 can promote proliferation of a non-small cell lung cancer cell line by dephosphorylating phosphoinositides, i.e., MINPP1 protein can promote proliferation of a non-small cell lung cancer cell line; peak et al disclose that a hypoxia-associated gene comprising MINPP1 can be used for prognostic test in patients with colorectal cancer.
However, the expression of MINPP1 in HBV-associated hepatocellular carcinoma patients and the regulation mechanism of MINPP1 after HBV infects host cells have not been reported yet. In addition, whether MINPP1 can be used as a new target point for resisting HBV-related hepatocellular carcinoma has not been researched yet.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a new target spot which can be effectively applied to the anti-HBV-related hepatocellular carcinoma.
In order to solve the technical problems, the invention provides an application of MINPP1 as a target molecule in preparing a drug for resisting HBV-related hepatocellular carcinoma.
As an improvement of the application of the invention: the growth and invasion of HBV related hepatoma cells are inhibited by over-expressing or activating MINPP1 gene. The mode for over-expressing or activating the MINPP1 gene expression is as follows: the MINPP1 gene is expressed in HBV-related hepatoma cells by an adenovirus vector or a lentivirus vector. Overexpression or activation of MINPP1 in HBV-associated hepatoma cells is mainly achieved by activating the function of MINPP1 in the 2, 3-diphosphoglycerate metabolic bypass, thereby reducing carbohydrate metabolism in cancer cells and thus reducing the growth and invasion of cancer cells.
The invention firstly confirms that the expression level of MINPP1 in hepatocellular carcinoma tissues has obvious correlation with whether the hepatocellular carcinoma is HBV-related or not. According to an embodiment of the present invention, the expression level of MINPP1 in HBV-associated hepatocellular carcinoma was significantly down-regulated compared to non-HBV-associated cellular carcinoma.
Further, the inventors found that MINPP1 has a significant correlation with the growth of HBV-associated hepatoma cells. According to the embodiment of the invention, the growth and invasion capacity of HBV related hepatoma cells can be promoted after the expression of MINPP1 gene is inhibited, and the growth and invasion capacity of HBV related hepatoma cells are obviously inhibited after the MINPP1 gene is over-expressed.
Furthermore, the invention finds that the expression of MINPP1 is mainly inhibited after HBV infects liver cancer cells, and the function of the MINPP1 in glycolysis/gluconeogenesis pathway is inhibited. According to the embodiment of the invention, after the expression of the MINPP1 gene is activated, the sugar metabolism can be inhibited, the generation of lactic acid and 2, 3-diphosphoglycerate can be inhibited, and the growth of tumor cells can be inhibited.
It is to be emphasized that: sabine tells that the MINPP1 protein can promote the proliferation of non-small cell lung cancer cell strains, and the invention is quite different from the invention, and proves that the MINPP1 plays a role in inhibiting the cell proliferation in HBV-related liver cancer cell strains.
The invention has the beneficial effects that: the invention proves that 2, 3-diphosphoglycerate metabolic bypass in glycolysis/gluconeogenesis metabolic pathway is inhibited by activating MINPP1 gene expression (leading MINPP1 gene to be over-expressed) in HBV-related hepatocellular carcinoma, thereby inhibiting the growth and invasion of HBV-related hepatoma cells. The invention proves that the MINPP1 gene can be used as an important target spot for effectively inhibiting the proliferation of HBV-related liver cancer cells.
Drawings
The following describes embodiments of the present invention in further detail with reference to the accompanying drawings.
FIG. 1 is a graph showing the determination of the expression level of MINPP1 in HBV-associated hepatocellular carcinoma tissues and non-HBV-associated hepatocellular carcinoma tissues by real-time fluorescent quantitative PCR; wherein, HBV + positive is HBV-related hepatocellular carcinoma, and HBV + negative is non-HBV-related hepatocellular carcinoma.
FIG. 2 shows the sequencing results of the whole transcriptome of HBV-associated hepatocellular carcinoma tissue and non-HBV-associated hepatocellular carcinoma tissue; wherein, "HBV (+) -T1-T7" represents liver cancer tissue samples of 7 patients with HBV-related hepatocellular carcinoma respectively, and "HBV (-) -T1-T7" represents liver cancer tissue samples of 7 patients with non-HBV-related hepatocellular carcinoma respectively.
FIG. 3 is The results of sequencing data for HBV-associated hepatocellular carcinoma and non-HBV-associated hepatocellular carcinoma in The U.S. tumor Genome map (The Cancer Genome Atlas, TCGA) database; wherein, HBV + positive is HBV-related hepatocellular carcinoma, and HBV + negative is non-HBV-related hepatocellular carcinoma.
FIG. 4 is a graph showing the real-time fluorescence quantitative PCR detection of the expression level of MINPP1 in HBV-related hepatoma cell lines and non-HBV-related hepatoma cell lines;
"Huh 7" is a non-HBV related hepatoma cell line, "Hep 3B" is an HBV related hepatoma cell line (A); and detecting the influence of (B) inhibition or (C) overexpression of MINPP1 gene on the cell proliferation capacity in the HBV-related hepatoma cell strain Hep 3B;
wherein, the 'Control' is a Hep3B cell, the 'siMINPP 1' is a Hep3B cell strain transfected with siRNA capable of inhibiting the expression of MINPP1, and the 'MINPP 1' is a Hep3B cell strain transfected with a plasmid capable of over-expressing MINPP 1.
FIG. 5 is a graph which shows that the scratch test analyzes the effect of HBV-related hepatoma cell line Hep3B on the proliferation and migration rate when the MINPP1 is inhibited or over-expressed;
a is a microscopic shooting picture of the cell growth state at 0h, 24h and 48h after scratching in the scratching experiment, and B is used for counting and calculating the migration rate of the three groups of cells in the graph 5A through ImageJ software;
wherein, the 'Control' is a Hep3B cell, the 'siMINPP 1' is a Hep3B cell strain transfected with siRNA capable of inhibiting the expression of MINPP1, and the 'MINPP 1' is a Hep3B cell strain transfected with a plasmid capable of over-expressing MINPP 1.
FIG. 6 shows the effect of MINPP1 on HBV-associated hepatoma cell proliferation as verified by nude mouse tumorigenicity experiments;
a is the change condition of tumor volume along with time after the tumor cells are inoculated to the nude mice subcutaneously;
the left picture of B is the picture of the experimental group (left, middle) and the control group mice (right) when the tumors are formed for 30 days, and the right picture is the picture of the tumor bodies stripped from the experimental group (below the dotted line) and the control group mice (above the dotted line) when the tumors are formed for 30 days;
wherein, the 'Control' is a mouse inoculated with Hep3B cells, and the 'MINPP 1' is a mouse inoculated with Hep3B cells capable of over-expressing MINPP 1.
FIG. 7 is a graph of the relationship of MINPP1 to the metabolic pathways associated with liver cancer as analyzed by transcriptome sequencing data;
a is to analyze the enrichment of differential genes in the "Glycolysis/Gluconeogenesis", "Sphingolipid signalling pathway", "Sphingolipid metabolism", "protein metabolism" and "Axon metabolism" pathways;
and B is correlation analysis of the difference gene and the metabolic pathway.
FIG. 8 is a graph showing the effect of HBV-associated hepatoma cell line Hep3B on the bypass of 2, 3-diphosphoglycerate metabolism when MINPP1 is inhibited or overexpressed;
in FIG. 8, A is a graph showing the measurement of glucose content in cell supernatants when MINPP1 was inhibited or overexpressed in Hep3B cells; b is measuring the content of lactic acid in cell supernatant when the MINPP1 is inhibited or over-expressed in Hep3B cells; c is to measure the content of 2, 3-diphosphoglycerate in cell supernatant when the MINPP1 is inhibited or overexpressed in Hep3B cells.
"Control" is Hep3B cells, "simrinpp 1" is inhibition of MINPP1 gene in Hep3B cells, "MINPP 1" is overexpression of MINPP1 gene in Hep3B cells.
Detailed Description
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto.
In one embodiment of the present invention, clinical samples were provided by the first hospital affiliated with the Zhejiang university medical college, and included 24 patients with HBV-associated hepatocellular carcinoma and 24 patients with non-HBV-associated hepatocellular carcinoma. Patients were confirmed by CT, histopathology and serology methods in combination with the relevant medical history, and the pathological tissues were obtained before treatment and approved by the ethical committee of Zhejiang university.
Description of the drawings: as used herein, the term "non-HBV-associated hepatocellular carcinoma" means that the liver cancer of a patient is caused by a non-HBV infection, and the term "non-HBV-associated hepatocellular carcinoma cell line" means that the liver cancer cell line does not contain any HBV-associated genetic information.
Example 1: determination of MINPP1 expression in HBV-and non-HBV-associated hepatocellular carcinomas
Tumor tissues of 24 cases of HBV-related hepatocellular carcinoma patients and tumor tissues of 24 cases of non-HBV-related hepatocellular carcinoma patients which are excised through surgical operation are respectively collected, and the specimens are placed in a refrigerator at the temperature of minus 80 ℃ for standby after collection. When extracting RNA from the tissue, the sample is taken out from a low-temperature refrigerator and thawed, 1mL of Trizol reagent is added per 100mg, an electric homogenizer is used for homogenization, and the mixture is kept standing for 5min after the homogenization. Adding 200 μ L of chloroform into the sample, shaking vigorously, standing for 5min, and centrifuging at 12000rpm for 15min in a centrifuge with precooling to 4 deg.C. And (3) after centrifugation, allowing the sample to separate, transferring the upper aqueous phase into a new centrifuge tube, adding isopropanol with the same volume, gently mixing uniformly, and standing at room temperature for 20-30 min. The sample in the centrifuge tube was centrifuged again for 10min and the supernatant solution was discarded. 1mL of 75% ethanol (DEPC water) was added to the sample and mixed gently, and then centrifuged at 10000rpm for 5min at 4 ℃. Centrifuging, discarding the supernatant, placing the centrifuge tube in an ultra-clean workbench for 5-10min to naturally dry the sample, adding appropriate amount of DEPC water, dissolving completely, and standing at 80 deg.C for use. After sample preparation, Reverse transcription PCR (RT-PCR) is used to Reverse-transcribe RNA extracted from the tissue into cDNA. To the reaction tube were added 2. mu.L of PCR buffer, 2. mu.L of cDNA, and 8. mu.L of DEPC water. The reaction conditions are as follows: 15min at 37 ℃; at 85 ℃ for 3 min; storing at 4 ℃. After obtaining the cDNA, the expression level of MINPP1 gene was measured by Quantitative real-time PCR (qPCR). mu.L of each of 10. mu.M forward and reverse primers, 0.5. mu.L, 1. mu.L of cDNA, 5. mu.L of LPCR buffer, and 3. mu.L of DEPC water were added to the reaction tube. The reaction conditions are as follows: at 95 ℃ for 30 s; 40 PCR cycles (95 ℃, 30 s; 60 ℃, 30 s); 95 ℃ for 15 s; 60 ℃ for 60 s; 95 ℃ for 15 s. The sequences of the primers used for qPCR were: 5'-GTCGCTCAGCCCCTATTTCG-3', and 5'-TGCGGATCTGTTTGACCGTG-3'.
The qPCR result is shown in FIG. 1, and it can be seen that MINPP1 has lower expression level in HBV-associated hepatocellular carcinoma tissue compared with non-HBV-associated hepatocellular carcinoma, indicating that the expression of the gene in this tissue is inhibited.
Further, 7 random RNA samples from the tissues (HBV-associated hepatocellular carcinoma and non-HBV-associated hepatocellular carcinoma) were sampled and sent to Nuo He Yuan science and technology Co., Ltd for whole transcriptome sequencing and analysis of the differential genes in the sequencing data, the results are shown in FIG. 2. Among genes associated with HBV infection and liver cancer, 9 genes including MINPP1 (ROBO2, ENPP4, PGM2, MINPP1, PIK3R1, SGPL1, LDHC, SMPD1, POLR1E) were lower in expression level in HBV-associated hepatocellular carcinoma tissue compared to non-HBV-associated hepatocellular carcinoma tissue, and the other 10 genes (WNT5A, FSTL4, MLPH, KLHL34, CAPZA3, TBC1D31, KISS1R, HTR4, TP53TG3D, SKIDA1) were higher in expression level in HBV-associated stem cell carcinoma tissue compared to non-HBV-associated stem cell carcinoma tissue. Of these, MINPP1 was most significantly inhibited in HBV-associated hepatocellular carcinoma tissues.
Furthermore, The present invention retrieves The published sequencing data of HBV-related hepatocellular carcinoma and non-HBV-related hepatocellular carcinoma samples from The Cancer Genome Atlas (TCGA) database, and compares The expression levels of The differential gene MINPP1 in different tissues, and as a result, as shown in fig. 3, it can be seen that The expression level of MINPP1 gene in hepatocellular carcinoma tissue caused by HBV is significantly lower than that of non-HBV-related hepatocellular carcinoma.
The above results show that the expression level of MINPP1 gene is closely related to whether it is HBV-induced hepatocellular carcinoma, and the expression level of the gene in HBV hepatocellular carcinoma tissues is significantly negatively regulated.
Example 2: the MINPP1 gene can inhibit the growth and invasion of HBV-related hepatoma cells
In this example, a strain of HBV-related hepatoma cell line Hep3B and a strain of non-HBV-related hepatoma cell line Huh7 were selected and spread on cell culture dishes containing DMEM medium (containing 10% fetal calf serum and 1% penicillin/streptomycin), and placed in a carbon dioxide incubator (37 ℃, 5% CO)2) Culturing until the number of cells is about 1 × 106cells were collected at cell/mL. The RNA of the cells was extracted by the same method as in example 1, and relative expression of MINPP1 was determined in the two cells by RT-PCR and qPCR experiments, and as a result, as shown in a of fig. 4, it can be seen that the expression level of the MINPP1 gene in Hep3B cells was significantly lower than that in Huh7 cells under the same culture conditions.
Further, the effect of MINPP1 on the growth of HBV-associated liver cancer cells was determined by cell proliferation assay reagents. Transfection of siRNA specific for the MINPP1 gene or transfection of a plasmid overexpressing the MINPP1 gene was used to inhibit or activate the expression of the MINPP1 gene in Hep3B cells, and compared to Hep3B cells. The siRNA specific to MINPP1 gene was synthesized by Suzhou Jima Biotech Co., Ltd as one of nucleotide sequences including 5'-CCUGGCAAUUAAAGGUGUUTT-3', 5'-GCAGUUGAACAGAAACAAATT-3' and 5'-CCUCGAACCUGAUAUUUGUTT-3'. The MINPP1 gene overexpression plasmid is constructed by committee of the Industrial bioengineering (Shanghai) Co., Ltd, and the plasmid vector is pcDNA3.1. And respectively adding 10 mu L of CCK8 solution into the cell culture holes at 48h after transfection, placing the culture dish into a carbon dioxide incubator for incubation for 4h, and measuring the absorbance value at 450nm by using an enzyme-labeling instrument. The results are shown in B, C of FIG. 4: it can be seen that the proliferation rate of Hep3B cells was enhanced and significantly higher than the control group (B of fig. 4) after further inhibiting the expression of the MINPP1 gene; while the proliferation rate of Hep3B was significantly reduced after compensating for the expression of the MINPP1 gene in Hep3B cells (C of FIG. 4).
Further, the effect of MINPP1 on the ability of cells to invade was determined by scratch assay. MINPP 1-specific siRNA or a plasmid overexpressing MINPP1 were transfected into Hep3B cells and compared to Hep3B cells. After 24h of transfection, the cell culture dish was scratched with a pipette tip and washed twice with PBS to remove the scraped cells. The growth state of the cells was observed and photographed at 0h, 24h and 48h after scratching, respectively, and the migration area and the mobility of the cells were analyzed and calculated using Image J software. The results are shown in a of fig. 5, and it can be seen from the under-mirror that Hep3B cells transfected with siRNA specific to MINPP1 grew and migrated at a significantly faster rate than the other two groups of cells (24 h after scratching), and at 48h the scratched cells had substantially confluent at both sides. However, the growth and migration rate of Hep3B cells after transfection with plasmid overexpressing MINPP1 was significantly reduced, and the confluency of cells was lowest at 24h and 48h after scratching compared to the control group and the siRNA-inhibited group. It can also be seen by calculating cell mobility that the mobility of Hep3B cells was increased when the expression of the MINPP1 gene was further inhibited by siRNA, and the mobility of Hep3B cells was decreased when the MINPP1 gene was overexpressed (fig. 5B).
The above results indicate that MINPP1 plays a tumor suppressor function in HBV-associated hepatocellular carcinoma, i.e., can suppress the growth and invasion of the associated cancer cells. However, MINPP1 gene was negatively regulated in HBV-associated hepatoma cells, increasing the growth rate of the cells.
Example 3: MINPP1 can inhibit tumor growth in animal models
In this example, the overexpression MINPP1 plasmid was first transfected into Hep3B cells and Hep3B cells were used as controls. Cells were harvested after transfection and cultured with serum-free DMEMResuspending the medium, adjusting to a cell concentration of 2X 107cell/mL, 100. mu.L of the cell suspension was inoculated subcutaneously into nude mice with a syringe, three per group. And (3) observing the tumor formation condition of the nude mice after inoculation and recording the tumor volume, killing the tumor-forming nude mice by using a neck-removing method on the 30 th day after inoculation, and taking pictures and recording after tumor body is stripped. As shown in A of FIG. 6, it can be seen that the tumor volume on the back side of the nude mice inoculated became gradually larger with the lapse of time, the tumor growth rate of the nude mice of the control group became significantly faster at day 13 after the inoculation, and the tumor volume of the nude mice of the control group was about 4 times that of the MINPP1 gene overexpression group by day 30. From the finally stripped tumor body, it can also be seen that the MINPP1 gene overexpression group is significantly smaller than the control group (FIG. 6B).
The results show that the MINPP1 is over-expressed in the HBV-related hepatoma cell strain Hep3B, the growth of tumors at the inoculation part of experimental animals can be effectively slowed down, and the MINPP1 gene can be used as a potential target spot for inhibiting HBV-related hepatocellular carcinoma.
Example 4: MINPP1 is mainly involved in the bypass of 2, 3-diphosphoglycerate metabolism in glycolysis/gluconeogenesis pathway and exerts related functions
In this example, after 7 sequencing of the tissue samples of HBV-related or unrelated hepatocellular carcinoma were first bioinformatically analyzed, and the results are shown in FIG. 7, it can be seen that the differential gene most related to HBV-related hepatocellular carcinoma was mainly enriched in the glycolysis/gluconeogenesis pathway (A in FIG. 7), in which MINPP1 gene is one of the main differential genes involved in the pathway (B in FIG. 7).
Furthermore, the influence of inhibition of MINPP1 gene expression or over-expression of MINPP1 gene on glycolysis/gluconeogenesis pathway in HBV-related liver cancer cell line Hep3B was analyzed by measuring the metabolic conditions of glucose, lactic acid and 2, 3-diphosphoglycerate, respectively. The results are shown in FIG. 8: it can be seen that when the expression of the MINPP1 gene in Hep3B cells was inhibited, glucose metabolism was enhanced and the production of lactic acid and 2, 3-diphosphoglycerate was promoted; when the MINPP1 gene was overexpressed, glucose metabolism and the production of lactate and 2, 3-diphosphoglycerate were reduced.
The above results indicate that MINPP1 is mainly involved in the bypass of 2, 3-diphosphoglycerate metabolism in glycolysis/gluconeogenesis metabolic pathway in HBV-related hepatocellular carcinoma, and activation of MINPP1 in HBV-related hepatoma cell line can effectively reduce carbohydrate metabolism in cancer cells and thus reduce energy acquisition of cancer cells.
Finally, it is also noted that the above-mentioned lists merely illustrate a few specific embodiments of the invention. It is obvious that the invention is not limited to the above embodiments, but that many variations are possible. All modifications which can be derived or suggested by a person skilled in the art from the disclosure of the present invention are to be considered within the scope of the invention.
Sequence listing
<110> Zhejiang university
<120> use of inositol polyphosphate phosphatase 1 as target molecule
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Claims (4)
1. Application of a carrier for over-expressing or activating MINPP1 gene in preparing a drug for resisting HBV-related hepatocellular carcinoma.
2. The use of the vector for overexpression or activation of MINPP1 gene according to claim 1 in the preparation of drugs for anti-HBV related hepatocellular carcinoma, wherein: the growth and invasion of HBV related hepatoma cells are inhibited by over-expressing or activating MINPP1 gene.
3. The use of the vector for overexpression or activation of MINPP1 gene according to claim 2, for preparing a drug for anti-HBV related hepatocellular carcinoma, wherein: the mode for over-expressing or activating the MINPP1 gene expression is as follows: the MINPP1 gene is expressed in HBV-related hepatoma cells by an adenovirus vector or a lentivirus vector.
4. The use of the vector for overexpression or activation of MINPP1 gene according to any one of claims 1 to 3 in the preparation of drugs for anti-HBV related hepatocellular carcinoma, wherein the vector comprises: overexpression or activation of MINPP1 in HBV-associated hepatoma cells is mainly achieved by activating the function of MINPP1 in the 2, 3-diphosphoglycerate metabolic bypass, thereby reducing carbohydrate metabolism in cancer cells and thus reducing the growth and invasion of cancer cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011123674.2A CN112245584B (en) | 2020-10-20 | 2020-10-20 | Use of polyphosphate inositol phosphatase 1 as target molecule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011123674.2A CN112245584B (en) | 2020-10-20 | 2020-10-20 | Use of polyphosphate inositol phosphatase 1 as target molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112245584A CN112245584A (en) | 2021-01-22 |
| CN112245584B true CN112245584B (en) | 2022-02-11 |
Family
ID=74245005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011123674.2A Active CN112245584B (en) | 2020-10-20 | 2020-10-20 | Use of polyphosphate inositol phosphatase 1 as target molecule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112245584B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009126970A1 (en) * | 2008-04-11 | 2009-10-15 | The Translational Genomics Research Institute | Method of assessing sensitivity to brostallicin |
| CN109811057A (en) * | 2019-03-27 | 2019-05-28 | 中山大学附属第六医院 | Application of the anoxic related gene in colorectal cancer forecasting system |
-
2020
- 2020-10-20 CN CN202011123674.2A patent/CN112245584B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009126970A1 (en) * | 2008-04-11 | 2009-10-15 | The Translational Genomics Research Institute | Method of assessing sensitivity to brostallicin |
| CN109811057A (en) * | 2019-03-27 | 2019-05-28 | 中山大学附属第六医院 | Application of the anoxic related gene in colorectal cancer forecasting system |
Non-Patent Citations (4)
| Title |
|---|
| Dysfunctional gene/protein networks in hepatitis C virus–induced hepatocellular cirrhosis and carcinoma;Tao Huang等;《ACM-BCB》;20100831;第502-507页 * |
| High expression of inositol polyphosphate phosphatase-like 1 associates with unfavorable survival in hepatocellular carcinoma;Maoying Fu等;《Int J Clin Exp Pathol》;20131231;第6卷(第11期);第2515-2522页 * |
| MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation;Jianxin Jiang等;《Oncotarget》;20150131;第6卷(第8期);第6359-6372页 * |
| Tumour cells can employ extracellular Ins(1,2,3,4,5,6)P6 and multiple inositol-polyphosphate phosphatase 1 (MINPP1) dephosphorylation to improve their proliferation;Sabine WINDHORST等;《Biochem. J.》;20131231;第115-125页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112245584A (en) | 2021-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110592216B (en) | Application of LRSAM1 as hepatocellular carcinoma molecular marker | |
| CN106834290A (en) | A kind of circular rna and application thereof | |
| US10123997B2 (en) | Target for treating hepatitis B virus | |
| CN107475386B (en) | Long-chain non-coding RNA marker for diagnosis and treatment osteosarcoma | |
| CN116637122B (en) | New application of circular RNA circ-DCUN1D4 in diagnosis and treatment of liver cancer | |
| CN111172290B (en) | MiRNA for diagnosis and treatment of hepatocellular carcinoma | |
| CN112245584B (en) | Use of polyphosphate inositol phosphatase 1 as target molecule | |
| CN110129451B (en) | Gastrointestinal malignant tumor marker and application thereof | |
| CN109371130B (en) | Application of RIPOR3 in preparation of biological products for breast cancer detection and treatment | |
| CN113549697B (en) | Gastric cancer heat chemotherapy sensitive marker and application thereof | |
| CN107012207B (en) | Application of LRP5 in clinical diagnosis and inhibition of digestive system tumors | |
| CN113456631B (en) | Small molecule drug targeting ACSL1 and application thereof in treatment of endometrial cancer | |
| CN112641797B (en) | Target and diagnostic marker for inhibiting colorectal cancer growth and metastasis and application thereof | |
| CN113637763A (en) | Application of miRNA biomarker in early diagnosis and treatment of melanoma | |
| CN111088357B (en) | Tumor marker for ESCC and application thereof | |
| CN116785310A (en) | Application of long-chain non-coding RNA OIP5-AS1 in inhibiting HBV positive liver cancer | |
| Renovaldi et al. | Expression of MicroRNA-155 in Hepatitis B Virus-Related to Hepatocellular Carcinoma | |
| CN112294960B (en) | Use of micro-molecule RNA-30b-5p as target molecule | |
| CN110042160B (en) | Digestive system malignant tumor marker and method for preparing medicine for inhibiting digestive system malignant tumor | |
| CN113368242B (en) | Application of non-small cell lung cancer inhibition target | |
| CN112980956B (en) | Target for inhibiting lung cancer growth and diagnostic marker uc.336 and application thereof | |
| CN113122638B (en) | Application of hsa-novel_circ_0006787 molecule in liver cancer treatment | |
| CN117737236A (en) | Application of PQLC2 gene in preparation of medicines for treating liver cancer and diagnostic kit | |
| CN113151280B (en) | Application of small-molecule non-coding RNA and host gene in diagnosis and treatment of gastric cancer | |
| CN113069465B (en) | Application of LINC00084 in preparation of hypoxia tumor radiotherapy auxiliary medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |